ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $137,400 | +11.4% | 12,000 | 0.0% | 0.01% | +9.1% |
| Q2 2023 | $123,360 | +33.2% | 12,000 | 0.0% | 0.01% | +22.2% |
| Q1 2023 | $92,640 | +5.0% | 12,000 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $88,200 | -48.7% | 12,000 | -50.0% | 0.01% | -10.0% |
| Q3 2022 | $172,000 | -19.6% | 24,000 | -4.5% | 0.01% | -16.7% |
| Q2 2022 | $214,000 | +25.1% | 25,120 | +103.2% | 0.01% | -29.4% |
| Q4 2021 | $171,000 | +58.3% | 12,360 | +3.0% | 0.02% | +54.5% |
| Q2 2021 | $108,000 | – | 12,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |